MARKET ACCESS INTELLIGENCE • Weekly Digest • May 8, 2026

Pricing White House projects $529B in MFN savings—but the math requires expanding deals to most sole-source branded drugs in the U.S.

The White House Council of Economic Advisers released a report (May 5) projecting $529 billion in domestic savings over 10 years from the MFN framework's prospective pricing component, which ties U.S. launch prices for new drugs to prices in high-income reference countries. A separate analysis using only the 2025 novel drug cohort yields $733 billion. The report also estimates $64.3 billion in Medicaid savings from applying MFN pricing to existing drugs through state supplemental rebates. FiercePharma reported that the savings figures depend critically on expanding agreements beyond the current 17 signatories. The report specifies that MFN supplemental rebates will not count toward Best Price calculations and thus will not directly affect 340B ceiling prices.

Biosimilar CVS Caremark expands biosimilar formulary to Stelara, MS, and rare blood disorders—most members at $0 out-of-pocket

CVS Health announced (May 5) that Caremark will transition brand Stelara to interchangeable biosimilars Pyzchiva (Samsung Bioepis/Cordavis) and Yesintek (Biocon) on commercial template formularies effective July 1, with most members paying $0. Chain Drug Review confirmed the expansion extends to biosimilar alternatives for Tysabri (natalizumab, with Briumvi and Tyruko) for MS and Soliris (eculizumab, with Epysqli) for rare blood disorders. This follows the April 1 transition of Prolia/Forteo to Cordavis's Ospomyv and Celltrion's Stoboclo for osteoporosis.

340B Seven GOP lawmakers back 340B rebate model as Louisiana AG prepares first state enforcement action

340B Report reported that seven Republican House members signed a letter to senior Trump administration health officials calling for "timely adoption" of the 340B rebate model. The letter arrives three weeks after the AHA's RFI response documented $72 million in average float costs per DSH hospital. Separately, Louisiana's attorney general is preparing enforcement actions against manufacturers violating the state's 340B contract pharmacy law—the first state-level enforcement since the 5th Circuit upheld the statute.

FORMULARY & BIOSIMILARS

• 340B Amphastar becomes 42nd manufacturer to impose 340B contract pharmacy restrictions — The 5th company to use Kalderos Truzo platform rather than 340B ESP, fragmenting 340B compliance infrastructure and forcing covered entities to manage submissions across multiple platforms simultaneously.
• Formulary CMS Administrator Oz: "Moving Prior Authorization into the 21st Century" — Blog criticizing PA as insurer tool for second-guessing clinicians, signaling regulatory action. Read alongside KFF's analysis of AI regulation in prior authorization, which documents growing state-level consumer protections against algorithmic claims denials.
• Formulary CMS and FDA announce RAPID coverage pathway for breakthrough devices — Streamlined Medicare coverage for FDA-designated Breakthrough Devices could establish the template for accelerated coverage decisions in specialty pharmaceuticals if CMS applies similar principles.
• Pricing Amgen and AbbVie confirm IRA negotiations impacted Q1 sales (Endpoints News) — First quarter where IRA Maximum Fair Prices are reflected in earnings data. AbbVie's simultaneous exposure across IRA, 340B patient definition lawsuit, and TrumpRx ($950 Humira) makes it the most watched multi-front pricing test case.

PRICING & REIMBURSEMENT

• Pricing Drug Channels: Where gross-to-net pressure actually lives after launch — ConnectiveRx analysis documents GTN exposures increasingly occurring at the claim level. Post-CAA 2026, as PBM compensation delinks, GTN pressure shifts from rebate negotiations to claim-level adjustments—creating new unpredictability for launch economics.
• Pricing PCMA: Pay-for-delay settlements keeping drug prices high — Documents a recent brand-generic settlement delaying competition. Frames patent abuse as the next reform target now that PBM reform is enacted—consistent with PCMA's April argument that delink was pharma's win.
• Policy AMCP publishes comprehensive state PBM reform inventory — Documents the rapidly fragmenting state-level landscape: different combinations of rebate pass-through mandates, spread pricing bans, any-willing-pharmacy requirements, and PBM licensure laws. The most current single-source reference for multi-state compliance.

POLICY & REGULATORY

• Policy MFN codification push meets resistance from industry, conservatives, and mid-sized pharma (FiercePharma) — 50+ conservative organizations oppose codification. Lilly CEO Ricks calls it "bad policy." Alkermes CEO Pops warns it could destroy smaller biopharma. Novartis CEO Narasimhan warns of major trade-offs within 18 months. Political viability before midterms remains uncertain.
• 340B Louisiana AG enforcement action: first proactive state-level 340B compliance — Uses authority upheld by 5th Circuit to impose penalties on manufacturers violating contract pharmacy access law. Active enforcement creates different dynamics than passive protections—manufacturers must comply or challenge fines directly.
• Policy PCMA: Employers and PBMs partnering against high drug prices — Repositions PBMs as employer allies against "Big Pharma's War on Generics," strategically timed ahead of DOL transparency rule finalization where PCMA argues the rule harms the very employer-PBM relationships it claims to champion.
• Policy FDA Commissioner Makary faces White House friction (STAT News) — Tensions between Makary and political staff raise questions about whether FDA's regulatory agenda—OTC switches, biosimilar guidance, RAPID pathway—will maintain momentum through the midterm cycle.

WHAT TO WATCH NEXT

MFN expansion letters to mid-sized pharma

The CEA report confirms the administration intends to reach "most manufacturers of sole-source brand name drugs." Astellas (no letter yet), Alkermes (warns of existential risk), and dozens of specialty pharma companies are on notice. Timing and scope of expansion letters will determine whether MFN remains a large-cap phenomenon or becomes market-wide.

CVS Caremark July 1 biosimilar transition

The largest single-day biosimilar formulary change in U.S. history: Stelara, Tysabri, and Soliris simultaneously moving to biosimilar alternatives. The 96% Humira transition rate is the benchmark, but MS and rare hematology populations are more clinically complex. The $0 member cost strategy should eliminate affordability barriers, making clinical inertia the primary variable.

Louisiana AG enforcement—will other states follow?

Louisiana's proactive enforcement creates a template for AGs in 5th and 8th Circuit states. A coordinated multi-state enforcement campaign would make national 340B restriction policies operationally unmanageable, even as the 4th Circuit and DOJ argue for preemption elsewhere. Mississippi, Arkansas, and Minnesota AGs are the next potential movers.